MYND Life Sciences Inc. announced the hiring of a Senior Operations and Research Manager and the resignation of a company officer. The company announced the hiring of Dr. Chaahat S.B Singh as the Company's Senior Operations and Research Manager. In 2019, Dr. Singh was awarded a PhD in Medical Genetics focusing on Central Nervous System (CNS) disorders at the University of British Columbia.

She has previously worked at Panacea Biotec Ltd. on the development of a Hepatitis B vaccine. Later Dr. Singh worked at the Institute of Microbial Technology, India, investigating the mechanisms underlying Drug-resistance in Tuberculosis. During her PhD, under the supervision of MYND's Chief Science Officer, Dr. Wilf Jefferies, Dr. Singh studied vascular dysfunction associated with Alzheimer's disease (AD), establishing an alternative mechanism to explain the blood-brain barrier disruption and disease pathology.

Most recently, Dr. Singh co-authored the eBioMedicine-The Lancet publication entitled "Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics," where Dr. Singh and colleagues explored the potential of anti-angiogenic small molecules used in cancer therapy as novel and promising therapeutics for AD.